BMJ 2000;321:1252-1255 ( 18 November )

Papers

Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study

Editorial by Mcgarrity

Christopher E Macdonald, research registrar, ^a Anthony C Wicks, consultant gastroenterologist, ^a Raymond J Playford, professor of gastroenterology. ^b

^a Leicester General Hospital NHS Trust, Leicester LE5 4PW, ^b Department of Gastroenterology, Hammersmith Hospital, London W12 0NN

Correspondence to: R J Playford r.playford{at}ic.ac.uk

Objectives: To review the benefit of an endoscopic surveillance programme for patients with Barrett's oesophagus.
Design: Observational study.
Setting: University teaching hospital.
Participants: 409 patients in whom Barrett's oesophagus was identified during 1984-94; 143 were entered into the annual surveillance programme.
Main outcome measures: Development of dysplasia and cancer and mortality.
Results: The average period of surveillance was 4.4 years; 55 patients were reassessed in 1994 but only eight remained in the programme in 1999, withdrawal being due to death (not from carcinoma of the oesophagus), illness, or frailty. Five of the patients who entered surveillance developed carcinoma of the oesophagus. Only one cancer was identified as a result of a surveillance endoscopy, the others being detected during endoscopy to investigate altered symptoms. Of the 266 patients who were not suitable for surveillance, one died from oesophageal cancer and 103 from other causes. Surveillance has resulted in 745 endoscopies and about 3000 biopsy specimens.
Conclusion: The current surveillance strategy has limited value, and it may be appropriate to restrict surveillance to patients with additional risk factors such as stricture, ulcer, or long segment (>80 mm) Barrett's oesophagus.

---

© BMJ 2000
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Surveillance for Barrett's oesophagus

J A Eksteen, Janusz A Jankowski, Christopher Paul Wild, David Forman, Richard A Carr, Ian L P Beales, R J Playford, A C B Wicks, and C E Macdonald
BMJ 2001 322: 1124. [Extract] [Full Text]

Surveillance of Barrett's oesophagus is of little benefit
BMJ 2000 321: 0. [Full Text]

Barrett's oesophagus: the continuing conundrum

Thomas J McGarrity
BMJ 2000 321: 1238-1239. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Yousef, F., Cardwell, C., Cantwell, M. M., Galway, K., Johnston, B. T., Murray, L. (2008). The Incidence of Esophageal Cancer and High-Grade Dysplasia in Barrett's Esophagus: A Systematic Review and Meta-Analysis. Am J Epidemiol 168: 237-249 [Abstract] [Full text]  
• Odze, R D (2006). Diagnosis and grading of dysplasia in Barrett's oesophagus.. J. Clin. Pathol. 59: 1029-1038 [Abstract] [Full text]  
• Murray, L, Sedo, A, Scott, M, McManus, D, Sloan, J M, Hardie, L J, Forman, D, Wild, C P (2006). TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut 55: 1390-1397 [Abstract] [Full text]  
• (2006). Dilemmas in managing Barrett's oesophagus. DTB 44: 69-72 [Abstract] [Full text]  
• Lovat, L B, Johnson, K, Mackenzie, G D, Clark, B R, Novelli, M R, Davies, S, O'Donovan, M, Selvasekar, C, Thorpe, S M, Pickard, D, Fitzgerald, R, Fearn, T, Bigio, I, Bown, S G (2006). Elastic scattering spectroscopy accurately detects high grade dysplasia and cancer in Barrett's oesophagus. Gut 55: 1078-1083 [Abstract] [Full text]  
• Wongsurawat, V. J., Finley, J. C., Galipeau, P. C., Sanchez, C. A., Maley, C. C., Li, X., Blount, P. L., Odze, R. D., Rabinovitch, P. S., Reid, B. J. (2006). Genetic Mechanisms of TP53 Loss of Heterozygosity in Barrett's Esophagus: Implications for Biomarker Validation.. Cancer Epidemiol. Biomarkers Prev. 15: 509-516 [Abstract] [Full text]  
• Cook, M. B., Wild, C. P., Forman, D. (2005). A Systematic Review and Meta-Analysis of the Sex Ratio for Barrett's Esophagus, Erosive Reflux Disease, and Nonerosive Reflux Disease. Am J Epidemiol 162: 1050-1061 [Abstract] [Full text]  
• Sharma, P, Sidorenko, E I (2005). Are screening and surveillance for Barrett's oesophagus really worthwhile?. Gut 54: i27-i32 [Abstract] [Full text]  
• Chang, J. T., Katzka, D. A. (2004). Gastroesophageal Reflux Disease, Barrett Esophagus, and Esophageal Adenocarcinoma. Arch Intern Med 164: 1482-1488 [Abstract] [Full text]  
• (2004). Abstracts. Gut 53: a1-a123 [Full text]  
• Murray, L., Watson, P., Johnston, B., Sloan, J., Mainie, I. M. L., Gavin, A. (2003). Risk of adenocarcinoma in Barrett's oesophagus: population based study. BMJ 327: 534-535 [Full text]  
• Heading, R C (2003). Barrett's oesophagus: epidemiology comes up with a surprise. Gut 52: 1079-1080 [Full text]  
• Anderson, L A, Murray, L J, Murphy, S J, Fitzpatrick, D A, Johnston, B T, Watson, R G P, McCarron, P, Gavin, A T (2003). Mortality in Barrett's oesophagus: results from a population based study. Gut 52: 1081-1084 [Abstract] [Full text]  
• Doak, S H, Jenkins, G J S, Parry, E M, D'Souza, F R, Griffiths, A P, Toffazal, N, Shah, V, Baxter, J N, Parry, J M (2003). Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus. Gut 52: 623-628 [Abstract] [Full text]  
• Basu, K K, Pick, B, Bale, R, West, K P, de Caestecker, J S (2002). Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium. Gut 51: 776-780 [Abstract] [Full text]  
• Playford, R J (2002). Endoscopic surveillance of patients with Barrett's oesophagus. Gut 51: 314-315 [Full text]  
• Allum, W H, Griffin, S M, Watson, A, Colin-Jones, D (2002). Guidelines for the management of oesophageal and gastric cancer. Gut 50 : v1-v23 [Full text]  
• Basu, K K, de Caestecker, J S (2002). Surveillance in Barrett's oesophagus: a personal view. Postgrad. Med. J. 78: 263-268 [Abstract] [Full text]  
• Spechler, S. J. (2002). Barrett's Esophagus. NEJM 346: 836-842 [Full text]  
• Alison, M R, Hunt, T, Forbes, S J (2002). Minichromosome maintenance (MCM) proteins may be pre-cancer markers. Gut 50: 290-291 [Full text]  
• Going, J J, Keith, W N, Neilson, L, Stoeber, K, Stuart, R C, Williams, G H (2002). Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa. Gut 50: 373-377 [Abstract] [Full text]  
• Eksteen, J., Latchford, A, Thomas, S., Jankowski, J. (2001). Commentary: Regional variations in oesophageal and gastric cardia cancers--implications and practice. Int J Epidemiol 30: 1425-1427 [Full text]  
• Eksteen, J A, Jankowski, J. A, Wild, C. P., Forman, D., Carr, R. A, Beales, I. L P, Playford, R J, Wicks, A C B, Macdonald, C E (2001). Surveillance for Barrett's oesophagus. BMJ 322: 1124-1124 [Full text]  
• (2001). How Intense Does Barrett's Surveillance Need to Be?. JWatch General 2001: 1-1 [Full text]  
• McGarrity, T. J (2000). Barrett's oesophagus: the continuing conundrum. BMJ 321: 1238-1239 [Full text]  

Rapid Responses:

Read all Rapid Responses

Surveillance In Barretts Oesophagus

Roger Ferguson
bmj.com, 20 Nov 2000 [Full text]

surveillance endoscopy should never be discouraged

Helen Dresner
bmj.com, 3 Feb 2001 [Full text]

Studies on screening in Barrett's oesophagus must be relevent to modern practice

Ian Beales
bmj.com, 28 Nov 2000 [Full text]

Hung jury on surveillance for Barrett's oesophagus: inadequate data

Rebecca C Fitzgerald
bmj.com, 30 Nov 2000 [Full text]

Re: Hung jury on surveillance for Barrett's oesophagus: inadequate data

R J Playford
bmj.com, 4 Dec 2000 [Full text]

Re: Studies on screening in Barrett's oesophagus must be relevent to modern practice

R J Playford
bmj.com, 4 Dec 2000 [Full text]

Biomarkers to refine surveillance of Barrett's oesophagus patients

Christopher Wild
bmj.com, 9 Jan 2001 [Full text]

Online poll

Find out more on doc2doc >>